top of page

Study to Assess the Effects of Intranasal Ketamine Along With rTMS for Patients With Treatment-resistant Major Depressive Disorder (TRD)

About the study

NCT Trial Number

NCT04352621

The drug being studied

Ketamine

noun_Drug_2240951.png
noun_Institution_118530.png

Sponsored by

University of Cincinnati

noun_date_3237048.png

Trial Start Date

May-20

noun_capsule_138144.png

About the participants

Age seeking

18 Years to 65 Years

gender

All

noun_Mental Health_2683241.png

Primary condition of volunteers accepted

Depression

noun_square_138133.png

Accepts healthy volunteers?

​

A study to assess the safety, tolerability, and effects of intranasal Ketamine in combination with rTMS for patients with treatment-resistant major depressive disorder (TRD). Patients will be given a dose of ketamine followed by 6 weeks of rTMS treatment.

Eyes Graffiti

Locations

United States, Cincinnati
University of Cincinnati


Contact: Jade Lord
513-558-4997
lordje@ucmail.uc.edu

Contact: Erik Nelson, MD
513-558-5115
nelsoneb@ucmail.uc.edu

​

​

​

​

Get in contact

Find a study site convenient for you below, then email yourself the contact details and next steps

bottom of page